Vigil Neuroscience to Present at the Stifel 2025 Virtual CNS Forum

Company Overview - Vigil Neuroscience, Inc. is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases by restoring the function of microglia, the immune cells of the brain [3] - The company is developing precision-based therapies to improve the lives of patients and their families, utilizing modern neuroscience drug development tools across multiple therapeutic modalities [3] Lead Clinical Candidates - Vigil's lead clinical candidate, Iluzanebart, is a fully human monoclonal antibody agonist targeting TREM2, aimed at treating adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease [3] - The company is also developing VG-3927, a novel small molecule TREM2 agonist, with an initial focus on Alzheimer's disease (AD) [3] Upcoming Events - Management will participate in a fireside chat at the Stifel 2025 Virtual CNS Forum on March 19, 2025, at 9:00 a.m. ET [1] - A live webcast of the event will be available, and an archived version will be accessible for approximately 90 days following the event [2]